BiotechTube

atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Attention Deficit Hyperactivity Disorder

Conditions

Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder

Trial Timeline

Oct 1, 2004 → May 1, 2008

NCT ID
NCT00192023

About atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day

atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day is a phase 3 stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00192023. Target conditions include Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Attention Deficit Hyperactivity Disorder were approved

Approved (20) Terminated (3) Active (0)
✅atomoxetineEli LillyApproved
✅AtomoxetineEli LillyApproved
✅Atomoxetine HydrochlorideEli LillyApproved
✅AtomoxetineEli LillyApproved
✅Atomoxetine hydrochloride + PlaceboEli LillyApproved
✅Atomoxetine + PlaceboEli LillyApproved
✅AtomoxetineEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00192023Phase 3Completed

Competing Products

20 competing products in Attention Deficit Hyperactivity Disorder

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
39
Atomoxetine + PlaceboEli LillyPhase 2/3
38
AtomoxetineEli LillyApproved
35
Atomoxetine HydrochlorideEli LillyApproved
43
AtomoxetineEli LillyPhase 3
40
AtomoxetineEli LillyApproved
43
Atomoxetine hydrochloride + PlaceboEli LillyApproved
43
CLONICEL (Clonidine HCl sustained release)ShionogiPhase 3
40
Donepezil hydrochloride + PlaceboEisaiPhase 3
40
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)Eli LillyPhase 2/3
38
Atomoxetine + PlaceboEli LillyApproved
43
AtomoxetineEli LillyApproved
43
AtomoxetineEli LillyPre-clinical
26
Atomoxetine HydrochlorideEli LillyApproved
43
Atomoxetine hydrochlorideEli LillyPhase 3
40
Atomoxetine Hydrochloride + PlaceboEli LillyApproved
43
atomoxetineEli LillyPhase 3
40
Atomoxetine HydrochlorideEli LillyApproved
43
Atomoxetine HydrochlorideEli LillyPhase 3
40
Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + PlaceboEli LillyPhase 3
40